Interleukin-6 is a biomarker for the development of fatal severe acute respiratory syndrome coronavirus 2 pneumonia
A Santa Cruz, A Mendes-Frias, AI Oliveira… - Frontiers in …, 2021 - frontiersin.org
Hyper-inflammatory responses induced by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) are a major cause of disease severity and death. Predictive prognosis …
(SARS-CoV-2) are a major cause of disease severity and death. Predictive prognosis …
Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial
Acute respiratory distress syndrome (ARDS) in COVID-19 is associated with high mortality.
Mesenchymal stem cells are known to exert immunomodulatory and anti-inflammatory …
Mesenchymal stem cells are known to exert immunomodulatory and anti-inflammatory …
Mechanisms and regulation of cellular senescence
L Roger, F Tomas, V Gire - International journal of molecular sciences, 2021 - mdpi.com
Cellular senescence entails a state of an essentially irreversible proliferative arrest in which
cells remain metabolically active and secrete a range of pro-inflammatory and proteolytic …
cells remain metabolically active and secrete a range of pro-inflammatory and proteolytic …
Delayed production of neutralizing antibodies correlates with fatal COVID-19
Recent studies have provided insights into innate and adaptive immune dynamics in
coronavirus disease 2019 (COVID-19). However, the exact features of antibody responses …
coronavirus disease 2019 (COVID-19). However, the exact features of antibody responses …
[HTML][HTML] An immune-based biomarker signature is associated with mortality in COVID-19 patients
Immune and inflammatory responses to severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) contribute to disease severity of coronavirus disease 2019 (COVID-19) …
(SARS-CoV-2) contribute to disease severity of coronavirus disease 2019 (COVID-19) …
Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long COVID symptoms
K Son, R Jamil, A Chowdhury… - European …, 2023 - Eur Respiratory Soc
Background Autoimmunity has been reported in patients with severe coronavirus disease
2019 (COVID-19). We investigated whether anti-nuclear/extractable-nuclear antibodies …
2019 (COVID-19). We investigated whether anti-nuclear/extractable-nuclear antibodies …
Senolytics reduce coronavirus-related mortality in old mice
INTRODUCTION The COVID-19 pandemic revealed enhanced vulnerability of the elderly
and chronically ill to adverse outcomes upon severe acute respiratory syndrome coronavirus …
and chronically ill to adverse outcomes upon severe acute respiratory syndrome coronavirus …
Efficacy of tocilizumab in patients hospitalized with Covid-19
JH Stone, MJ Frigault, NJ Serling-Boyd… - … England Journal of …, 2020 - Mass Medical Soc
Background The efficacy of interleukin-6 receptor blockade in hospitalized patients with
coronavirus disease 2019 (Covid-19) who are not receiving mechanical ventilation is …
coronavirus disease 2019 (Covid-19) who are not receiving mechanical ventilation is …
Tocilizumab in hospitalized patients with severe Covid-19 pneumonia
IO Rosas, N Bräu, M Waters, RC Go… - … England Journal of …, 2021 - Mass Medical Soc
Abstract Background Coronavirus disease 2019 (Covid-19) is associated with immune
dysregulation and hyperinflammation, including elevated interleukin-6 levels. The use of …
dysregulation and hyperinflammation, including elevated interleukin-6 levels. The use of …
Cytokine profiles associated with acute COVID-19 and long COVID-19 syndrome
MAF Queiroz, PFM Neves, SS Lima… - Frontiers in cellular …, 2022 - frontiersin.org
The duration and severity of COVID-19 are related to age, comorbidities, and cytokine
synthesis. This study evaluated the impact of these factors on patients with clinical …
synthesis. This study evaluated the impact of these factors on patients with clinical …